Bertis, a precision medicine development firm, said Tuesday that it would cooperate with the National Cancer Center Research Institute (NCCRI) to research and develop a proteomics-based cancer diagnosis and treatment.

The company added that the two partners would actively collaborate to conduct clinical trials for cancer diagnosis and treatment and develop proteomic-based biomarker discovery from several types of cancer tissues and blood samples.

Proteomics has recently attracted public attention as a key to precision medicine for early diagnosis and personalized treatment and as a diagnostic technology that analyzes the function and structure of proteins to study the mechanism and therapeutics of diseases, according to Bertis.

Both organizations plan to initiate joint research and clinical trials to develop cancer diagnosis and treatment by exchanging the core technologies of quantitative proteomics of Bertis and the cancer research capabilities of NCCRI.

“We are happy to work with NCCRI, which plays a leading role in cancer research based on world-class data and technology,” Bertis CEO Han Seung-man said. “Our company will do its best to contribute to research and development by sharing accumulated know-how and core technology as a leading proteomics company to fight cancer, which is the highest cause of death in Korea.”

Bertis said it has built 25 million protein libraries through research over the past decade and is developing multi-marker diagnostic technologies for various diseases.

The company has commercialized Mastocheck, the blood test-based world’s first proteomic-analytic breast cancer early diagnosis solution, and widened its service over a cancer diagnosis, including pancreatic and ovarian cancer. It also tries to promote precision medicine by developing markers for personalized treatment based on treatment mechanisms built from quantified libraries and patient protein information.